Current Report Filing (8-k)
06 July 2019 - 6:07AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
June 30, 2019
AVADEL
PHARMACEUTICALS PLC
(Exact
name of registrant as specified in its charter)
Ireland
|
|
001-37977
|
|
98-1341933
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
Block 10-1
|
Not Applicable
|
Blanchardstown Corporate Park,
Ballycoolin
|
(Zip Code)
|
Dublin 15, Ireland
|
|
(Address of Principal Executive Offices)
|
|
R
egistrant’s
telephone number, including area code:
+353 1 485 1200
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Ticker symbol(s)
|
|
Name of each exchange on which registered
|
American Depositary Shares*
|
|
|
|
NASDAQ Stock Market LLC
|
Ordinary Shares**
|
|
AVDL
|
|
(NASDAQ Global Market)
|
|
*
|
American Depositary Shares may be evidenced by American
Depository Receipts. Each American Depositary Share represents one (1) Ordinary Share.
|
|
**
|
Nominal value $0.01 per share. Not for trading, but
only in connection with the listing of American Depositary Shares.
|
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
|
On June 30, 2019, David P. Gusky resigned from his position
as the Corporate Controller & Chief Accounting Officer of Avadel Pharmaceuticals plc (the “Company”) and from all
other positions he holds with the Company and each of its subsidiaries. In his capacity as Corporate Controller and Chief Accounting
Officer, Mr. Gusky had served as the Company’s principal accounting officer. Mr. Gusky’s resignation is not the result
of any dispute or disagreement with the Company. Upon Mr. Gusky’s resignation, Michael F. Kanan, the Company’s Senior
Vice President, Chief Financial Officer, and principal financial officer, assumed the responsibilities of principal accounting
officer.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AVADEL PHARMACEUTICALS PLC
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Phillandas T. Thompson
|
|
|
|
Phillandas T. Thompson
|
|
|
|
Senior Vice President, General Counsel and
Corporate Secretary
|
Date: July 5, 2019
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Apr 2024 to May 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From May 2023 to May 2024